Table 2.
Comparison of treatment response after treatment
| Items | Regorafenib plus DEB-TACE (N = 34) | Regorafenib (N = 42) | W/χ2 | P value |
|---|---|---|---|---|
| Total treatment response | 1019.000 | 0.001 | ||
| CR, no. (%) | 2 (5.9) | 0 (0.0) | ||
| PR, no. (%) | 10 (29.4) | 3 (7.1) | ||
| SD, no. (%) | 14 (41.2) | 17 (40.5) | ||
| PD, no. (%) | 8 (23.5) | 22 (52.4) | ||
| ORR, no. (%) | 12 (35.3) | 3 (7.1) | 9.400 | 0.002 |
| DCR, no. (%) | 26 (76.5) | 20 (47.6) | 6.546 | 0.011 |
DEB-TACE drug-eluting bead transarterial chemoembolization, CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, DCR disease control rate
Comparison was determined by Wilcoxon rank sum test or chi-squared test